• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Recordati News

    48,94 € +0,37% +0,18 €
    26.04.24 21:43:08 Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0EABR
    ISIN: IT0003828271
    US-Symbol: RCDTF
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 12,60
    ME73C7

    Recordati News

    10.05.22 - PLX
    Recordati Q1 Earnings Better Than Expected; FY Targets Confirmed
    (PLX AI) – Recordati Q1 revenue EUR 419.4 million vs. estimate EUR 408 million. • Q1 EBITDA EUR 163 million vs. estimate EUR 152 million • Still sees FY revenue EUR 1,720-1,780 ...
    24.02.22 - PLX
    Recordati FY Earnings in Line with Consensus; Sees Growth in 2022
    (PLX AI) – FY revenue EUR 1,580 million vs. estimate EUR 1,578 million • FY EBITDA EUR 602 million vs. estimate EUR 603 million • Recordati 2022 objectives continued growth in ...
    03.12.21 - PLX
    Recordati Buys EUSA Pharma; Enterprise Value EUR 750 Million
    (PLX AI) – Recordati buys EUSA Pharma for Enterprise Value EUR 750 million. • EUSA Pharma is a global specialty pharmaceutical company with headquarters in theUnited ...
    29.07.21 - PLX
    Recordati H1 EBITDA EUR 300.5 Million; FY Outlook Unchanged
    (PLX AI) – Recordati half year revenue EUR 771 million. • H1 EBITDA EUR 300.5 million • Full year outlook unchanged • Says Q2 partial recovery in the Group’s main reference markets ...
    09.07.21 - PLX
    Recordati Starts Process to Strengthen Corporate Governance
    (PLX AI) – Recordati says started process to strengthen corporate governance. • Refers to media reports • Says the process aims to support the medium and long term development of ...
    23.03.21 - GlobeNewswire
    RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE
    RECORDATI :   POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND ...
    22.02.21 - GlobeNewswire
    RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.
    RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.
    29.01.21 - GlobeNewswire
    RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
    RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
    30.11.20 - GlobeNewswire
    RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY
    RECORDATI:  MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY Milan, 30 November 2020 – ...
    29.10.20 - GlobeNewswire
    RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%
    RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES - 0.6 %, EBITDA + 7.1 %, ADJUSTED NET INCOME +12.3%
    01.10.20 - GlobeNewswire
    RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED
    RECORDATI:  MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED
    21.09.20 - GlobeNewswire
    RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
    RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION Milan, 21 September, 2020 - Recordati announces ...
    30.07.20 - GlobeNewswire
    RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8%
    RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES + 2.3 %, EBITDA + 11.4 %, ADJUSTED NET INCOME +16.8%
    17.06.20 - GlobeNewswire
    RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE
    RECORDATI: ISTURISA ® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE
    07.05.20 - GlobeNewswire
    RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
    RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES + 12.1 %, EBITDA + 20.1 %.
    29.04.20 - GlobeNewswire
    RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
    RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018).
    08.04.20 - GlobeNewswire
    Recordati Rare Diseases now holds Isturisa® European MA
    Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa ® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome
    26.03.20 - GlobeNewswire
    RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
    RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
    18.03.20 - GlobeNewswire
    RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19
    RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19 Milan, 18 March 2020 – Recordati ...
    18.03.20 - GlobeNewswire
    BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%)
    BOARD APPROVES THE 2019 ACCOUNTS.  SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%).

    Newssuche

    Videos

    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »